Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label IMC-A12 monotherapy in previously treated advanced or metastatic soft tissue sarcoma and Ewing's sarcoma/PNET
NL-OMON33655Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cixutumumab in Ewing sarcoma of bone, Peripheral Primitive Neuroectodermal Tumor (pPNET), soft tissue sarcoma (STS) and 4 more, sponsored by Eli Lilly and Company. Primary endpoint: 12-week progression-free survival rate. Started Jul 2009; status: active, not recruiting.
02
Drugs
cixutumumab
03
Conditions
Ewing sarcoma of bonePeripheral Primitive Neuroectodermal Tumor (pPNET)soft tissue sarcoma (STS)rhabdomyosarcoma (RMS)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NL-OMON33655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33655.